“…The specificity of most MMPs is surprisingly similar, which makes it very difficult to design the much desired inhibitors that target individual MMPs, which are involved in cancer. Thus, the binding of inhibitors to various metalloproteases was investigated using QM/MM approaches since around the year 2000, e.g., for MMP1, MMP3, MMP9, carboxypeptidase A, and glutamate carboxypeptidase II [ 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 ]. A comparative study on MMP1-3, MMP8, MMP9, and MMP13 confirmed the good correlation of computed and experimental free binding energies of inhibitors, while a cross-docking matrix gave hints to rational design of more specific MMP inhibitors [ 68 ].…”